Programmed Death Ligand-1 and Tumor Mutation Burden Testing of Patients With Lung Cancer for Selection of Immune Checkpoint Inhibitor Therapies

Publication Date: April 16, 2024
Last Updated: April 19, 2024

Summary of Recommendations

In patients with advanced non–small cell lung cancer, pathologists should use a validated PD-L1 immunohistochemistry expression assay, in conjunction with other targetable genomic biomarker assays where appropriate, to optimize selection for treatment with immune checkpoint inhibitors. (S, M )
620

Overview

Title

Programmed Death Ligand-1 and Tumor Mutation Burden Testing of Patients With Lung Cancer for Selection of Immune Checkpoint Inhibitor Therapies

Authoring Organizations